<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489617</url>
  </required_header>
  <id_info>
    <org_study_id>15-174</org_study_id>
    <nct_id>NCT02489617</nct_id>
  </id_info>
  <brief_title>The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy</brief_title>
  <official_title>The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying a surgical intervention to rule out the presence of cancer in
      participants that have been diagnosed with flat epithelial atypia (FEA) or intraductal
      papilloma without atypia (IPWA) by core needle biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast milk is made in lobules and is carried through the ducts toward the nipple. Normal
      ducts are lined by one layer of cells very similar to each other in appearance. Flat
      epithelia atypia (FEA) and intraductal papilloma without atypia (IPWA) are changes seen
      within the milk ducts. In the recent years these lesions have been seen more often, seemingly
      because more core needle biopsies are being done with the help of a mammogram, ultrasound or
      breast MRI. The reason for this is there is new technology available which is able to do such
      biopsies. A core needle biopsy uses a hollow needle to remove samples of tissue from the
      breast. This is an accurate method that does not involve surgery.

      FEA and IPWA are not very common and there are few research studies addressing them. Women
      found to have FEA or IPWA on core biopsy results may receive conflicting recommendations
      about how to precede next. It is unclear if more tissue should be removed from the biopsy
      site to ensure that there is no cancer nearby.

      The purpose of this study is to find out how often cancer is identified by excisional biopsy
      near an initial core biopsy where FEA or IPWA has previously been seen. Depending on these
      findings doctors will be better able to advise their patients as to whether they need to have
      a surgical biopsy, when FEA or IPWA are seen on needle biopsy, to rule out the presence of
      breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of invasive carcinoma and/or DCIS in patients originally diagnosed with FEA or IPWA on core biopsy, based on local pathology review</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of invasive carcinoma and/or DCIS in patients originally diagnosed with FEA or IPWA on core biopsy, based on central pathology review</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">221</enrollment>
  <condition>Flat Epithelia Atypia</condition>
  <condition>Intraductal Papilloma Without Atypia</condition>
  <arm_group>
    <arm_group_label>Pathologic evaluation of excised tissue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).
-- Pathologic evaluation of excised tissue</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pathologic evaluation of excised tissue</intervention_name>
    <description>Up to 3 months after excisional biopsy</description>
    <arm_group_label>Pathologic evaluation of excised tissue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women all races and ethnic groups are eligible for this trial. This trial is open to
             the accrual of women only.

          -  Patients must be women

          -  Patients must be at least 18 years of age

          -  Patients must have an imaging abnormality that necessitated a core needle biopsy

          -  The imaging abnormality must have been categorized as Breast Imaging-Reporting and
             Data System (BIRADS) level 1-4 lesion

          -  There is documented concordance* between the initial breast imaging finding and the
             core biopsy pathology report. The core needle biopsy must contain FEA or IPWA,
             according to the local pathologist. (It is possible that the central pathology review
             which is done after the patient is registered on this protocol will have a diagnosis
             discrepant from that made by the original institution's pathologist. In that case, the
             study team will communicate this to the original institution's site investigator
             within one week of the date of the central pathology review having been finalized).
             Patients may have a personal history of prior or concurrent fibroadenoma and a prior
             history of proliferative breast lesions with or without atypia.

          -  Patients must be registered on study within 100 days after core needle biopsy.

          -  Patients must have an ability to understand and the willingness to sign a written
             informed consent document. The patient is still eligible for this study even if she
             declines consent for her tissue to be used for any (or all) of the correlative studies
             described in this document and/or if she declines consent for her tissue to go into a
             tissue bank for future unspecified research.

               -  Concordance is a determination by the radiologist (or his or her covering
                  provider) performing an image-guided core needle biopsy that the pathology report
                  from this procedure corresponds to the imaging appearance of a given lesion and
                  that the said lesion's most representative portion has been sampled.

        Exclusion Criteria:

          -  Personal history and/or concomitant diagnosis of invasive breast cancer or DCIS

          -  Palpable abnormality diagnosed by core needle biopsy to be FEA or IPWA

          -  Pathologic nipple discharge associated with IPWA (spontaneous bloody or clear
             persistent single duct discharge)

          -  A BIRADS 5 lesion

          -  Discordance between the initial breast imaging finding and the core biopsy pathology
             report

          -  The presence of atypical ductal hyperplasia (ADH) on core biopsy

          -  Known current pregnancy. A pregnancy test is not required for this exclusion criteria.

          -  Women who are breastfeeding

          -  Patient registered on study more than 100 days since the date of core needle biopsy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faina Nakhlis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faina Nakhlis, MD</last_name>
    <phone>617-983-7777</phone>
    <email>fnakhlis@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Parker, MD</last_name>
      <email>ccparker@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine Parker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna C. Willey, MD</last_name>
      <email>scw9@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Shawna C Willey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Willey, MD</last_name>
      <email>scw9@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Shawna Willey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Jacobs, MD</last_name>
      <email>ljacob14@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kandice Ludwig, MD</last_name>
      <email>kaludwig@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lina Sego</last_name>
      <email>lmsego@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kandice Ludwig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Willey, MD</last_name>
      <email>scw9@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Shawna Willey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Franklin Square Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Willey, MD</last_name>
      <email>scw9@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Shawna Willey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Jacobs, MD</last_name>
      <email>ljacob14@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Howard County General Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Jacobs, MD</last_name>
      <email>ljacob14@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faina Nakhlis, MD</last_name>
      <phone>617-983-7777</phone>
      <email>fnakhlis@partners.org</email>
    </contact>
    <investigator>
      <last_name>Faina Nakhlis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pilewskie, MD</last_name>
      <email>pilewskm@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Melissa Pilewskie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rouzan G Karabakhtsian, MD, PhD</last_name>
      <email>rkarabak@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Rouzan G Karabakhtsian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pilewskie, MD</last_name>
      <email>pilewskm@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Melissa Pilewskie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kandace McGuire, MD</last_name>
      <email>kandace_mcguire@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Kandace McGuire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Hwang, MD</last_name>
      <email>shelley.hwang@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Shelley Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Hillsborough Campus</name>
      <address>
        <city>Hillsborough</city>
        <state>North Carolina</state>
        <zip>27278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kandace McGuire, MD</last_name>
      <email>kandace_mcguire@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Kandace McGuire</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla McAuliffe, MD</last_name>
      <email>mcauliffepf@mwri.magee.edu</email>
    </contact>
    <investigator>
      <last_name>Priscilla McAuliffe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Faina Nakhlis, MD</investigator_full_name>
    <investigator_title>Faina Nakhlis, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Papilloma, Intraductal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

